基于智能手机的粪便检测在结直肠癌筛查中的性能:基于人群的研究
在德国南部胃肠病诊所招募2021至2023年间计划接受筛查结肠镜检查的个体,评估基于智能手机的粪便免疫化学检测(FIT)的可行性和诊断性能,并与实验室FIT比较。654名参与者中361人(55%)使用智能手机FIT,其中274人(76%)结果有效,643人(98%)使用实验室FIT。智能手机FIT对进展期肿瘤的敏感度为28%(95%CI 13%-47%),实验室FIT为34%(95%CI 18%-54%),两者特异度均为92%(95%CI 87%-95%)。
要点
- 智能手机FIT对进展期肿瘤敏感度28%(95%CI 13%-47%),实验室FIT为34%(95%CI 18%-54%),特异度均为92%。
- 361/654(55%)使用智能手机FIT,其中274/361(76%)结果有效;643/654(98%)使用实验室FIT。
- 89%认为智能手机FIT是实验室FIT的有用替代选择;未使用原因多为技术问题(47%)或一般顾虑(44%)。
核心结论
- 智能手机FIT可作为现有实验室FIT之外的替代选择。
研究设计与样本
- BLITZ研究为基于人群的研究,2021至2023年在德国南部胃肠病诊所招募计划接受筛查结肠镜检查的个体。
- 参与者同时接受智能手机FIT和实验室FIT;智能手机FIT由快速检测和智能手机应用程序组成,应用程序使用智能手机摄像头定量评估快速检测结果。
- 可行性通过自填问卷评估,两种FIT的比较性能通过敏感度、特异度和受试者工作特征曲线(ROC)指标评估。
主要发现
- 654名参与者中361人(55%)使用智能手机FIT,其中274人(76%)结果有效;643人(98%)使用实验室FIT。
- 89%认为智能手机FIT是实验室FIT的有用替代选择。
- 未使用智能手机FIT的原因主要为技术性(应用程序或智能手机相关,47%)或反映对此类检测的一般顾虑或态度(44%)。
- 智能手机FIT对进展期肿瘤的敏感度为28%(95%CI 13%-47%),实验室FIT为34%(95%CI 18%-54%),两者特异度相同,均为92%(95%CI 87%-95%)。
关键数值与推荐
- 智能手机FIT对进展期肿瘤的敏感度为28%(95%CI 13%-47%),实验室FIT为34%(95%CI 18%-54%)。
- 智能手机FIT和实验室FIT的特异度均为92%(95%CI 87%-95%)。
临床怎么用
- 作者认为智能手机FIT可作为现有实验室FIT之外的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Noninvasive colorectal cancer (CRC) screening bears high potential for increasing participation if implemented in a straightforward way. We have evaluated the feasibility and diagnostic performance of a smartphone-based fecal immunochemical test (FIT) for CRC screening and compared its performance with a laboratory-based FIT. METHODS: Individuals scheduled for a screening colonoscopy in gastroenterology practices in Southern Germany enrolled into the BLITZ study between 2021 and 2023 were offered a smartphone-based FIT and a laboratory FIT. The smartphone-based FIT consists of a rapid test and a smartphone app. The app quantitatively evaluates the result of the rapid test using the smartphone camera. The feasibility of the smartphone-based FIT was evaluated in a self-administered questionnaire. The comparative performance of the 2 FITs was evaluated by sensitivity, specificity, and receiver-operator curve (ROC) measures. RESULTS: Of 654 study participants who were offered both a smartphone-based FIT in addition to the laboratory FIT, 361 (55%) made use of the smartphone-based FIT, 274 (76%) of those had a valid smartphone-based FIT, and 643 (98%) used the laboratory FIT. Overall, 89% considered the smartphone-based FIT as a useful alternative offer to the laboratory FIT. The reasons why the smartphone-based FIT was not used were mostly technical (app- or smartphone-related, 47%) or reflecting more general concerns or attitudes towards such a test (44%). The smartphone-based FIT showed a sensitivity for advanced neoplasms (28%; 95% confidence interval [CI], 13%-47%) similar to the laboratory FIT (34%; 95% CI, 18%-54%) at an identical specificity (92%; 95% CI, 87%-95%). CONCLUSIONS: The smartphone-based FIT could serve as an alternative in addition to currently offered laboratory FITs. STUDY REGISTRATION: German Clinical Trials Register (drks.de), Number: DRKS00008737.
引用
- Hoffmeister M, Seum T, Ludwig L, et al. Performance of a Smartphone-based Stool Test for Use in Colorectal Cancer Screening: Population-based Study. Clin Gastroenterol Hepatol. 2025. PMID: 40403947. doi:10.1016/j.cgh.2025.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。